S'abonner

Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study - 24/04/13

Doi : 10.1016/j.jaad.2008.05.031 
David Pariser, MD a, , Robert Loss, MD b, Michael Jarratt, MD c, William Abramovits, MD d, James Spencer, MD e, Roy Geronemus, MD f, Philip Bailin, MD g, Suzanne Bruce, MD h
a Eastern Virginia Medical School, Division of Dermatology and Virginia Clinical Research Inc, Norfolk, Virginia 
b Dermatology Associates of Rochester, Rochester, New York 
c DermResearch Inc, Austin, Texas 
d Texas Dermatology Research Institute, Dallas, Texas 
e Spencer Dermatology and Skin Surgery Center, Saint Petersburg, Florida 
f Laser and Skin Surgery Center of NYC, New York, New York 
g Department of Dermatology, Cleveland Clinic Foundation, Cleveland, Ohio 
h Suzanne Bruce and Associates PA, The Center for Skin Research, Houston, Texas 

Correspondence to: David Pariser, MD, Eastern Virginia Medical School, Division of Dermatology and Virginia Clinical Research Inc, 301 Medical Tower, Norfolk, VA 23507.

Abstract

Background

The use of light-emitting diode light offers practical advantages in photodynamic therapy (PDT) with topical methyl-aminolevulinate (MAL) for management of actinic keratoses (AK).

Objective

We sought to evaluate the efficacy of MAL PDT using red light-emitting diode light.

Methods

We conducted a multicenter, double-blind, randomized study. A total of 49 patients with 363 AK lesions had 16.8% MAL cream applied under occlusion for 3 hours, and 47 patients with 360 AK lesions had vehicle cream similarly applied. The lesions were then illuminated (630 nm, light dose 37 J/cm2) with repeated treatment 1 week later. Complete lesion and patient (all lesions showing complete response) response rates were evaluated 3 months after last treatment.

Results

MAL PDT was superior (P < .0001) to vehicle PDT with respect to lesion complete response (86.2% vs 52.2%, odds ratio 6.9 [95% confidence interval 4.7-10.3]) and patient complete response (59.2% vs 14.9%, odds ratio 13.2 [95% confidence interval 4.1-43.1]).

Limitations

The study population may not be representative of all patients with AK.

Conclusion

MAL PDT using red light-emitting diode light is an appropriate treatment alternative for multiple AK lesions.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : AK, CI, LED, MAL, PDT


Plan


 Supported by PhotoCure ASA, Oslo, Norway.
 Disclosure: The authors certify that, to their knowledge, the work that is reported on in said manuscript has not received financial support from any pharmaceutical company or other commercial source except as described below. Neither the authors nor any first-degree relative have any special financial interest in the subject matter discussed in said manuscript. Dr Pariser has received grants for participation in clinical trials from PhotoCure ASA, Galderma, and DUSA. Dr Loss has received grants for participation in clinical trials from DOW, Genentech, Connetics, Allergan, Galderma, Hill, Centocor, Stiefel, and Novartis. Dr Abramovits has received grants for participation in clinical trials from Galderma. Dr Bruce has received grants for participation in clinical trials from Allergan, Medicis, Altana, Astellas, Galderma, 3M, Connetics, Obagi, Dow, DUSA, Hill, Isolagen, Novartis, Contura, and Anacor; has received honoraria for participation in advisory boards from Allergan and Syneron; has received honoraria as a consultant for Dermik and Medicis; and has received honoraria as a speaker for Dermik and Obagi. All authors received a grant for participation in this trial from PhotoCure ASA.
 Reprints not available from the authors.


© 2008  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 59 - N° 4

P. 569-576 - octobre 2008 Retour au numéro
Article précédent Article précédent
  • American Board of Dermatology Examination Dates
| Article suivant Article suivant
  • Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis
  • Brad A. Yentzer, Christopher B. Yelverton, Daniel J. Pearce, Fabian T. Camacho, Zaineb Makhzoumi, Adele Clark, Ann Boles, Alan B. Fleischer, Rajesh Balkrishnan, Steven R. Feldman

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.